Johnson & Johnson: Announcing a Lead Vaccine Candidate

  • April 29, 2020
  • Scott
  • 0 Comments

Another company on the front lines of the corona virus response is Johnson & Johnson:

The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.

J&J isn’t the only company pursuing vaccine candidates – we are hopeful that one or more of the candidates already being explored will prove effective in trials this fall.  Note the accelerated time table for all of these types of announcements.  BP3 has done quite a bit of work in the clinical trials area of Life Sciences and I have to say, we’re thrilled with how these companies are pushing the process forward in a time of real crisis.

More from the announcement:

As part of its commitment, Johnson & Johnson is also expanding the Company’s global manufacturing capacity, including through the establishment of new U.S. vaccine manufacturing capabilities and scaling up capacity in other countries. The additional capacity will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally. The Company plans to begin production at risk imminently and is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said, “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible. As the world’s largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic.”

Let’s wish them luck in this endeavor.  It’s heartening to see so much progress so quickly. More coverage from Forbes here.

 

 

 

Related Posts
  • May 21, 2020
  • Scott
  • 0 Comments

Sven Boermeester is an entrepreneur with a publishing business: he collects compelling stories about innovativ...

  • May 18, 2020
  • Scott
  • 0 Comments

In a moment where we all have some reasonable fear about our health, the health of our loved ones, and of our ...

  • May 17, 2020
  • Scott
  • 0 Comments

A recently published report on a survey by IDG (sponsored by a BPM software firm), on the subject of whether t...